Gwendoline J.D. Teske
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gwendoline J.D. Teske has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Loes Butter
Department of Pathology, Amsterdam UMC (location AMC), University of Amsterdam
2 shared publications - Lotte Kors
Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
2 shared publications Nike Claessen
Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
2 shared publications- Sandrine Florquin
Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
2 shared publications - Coert J. Zuurbier
L.E.I.C.A., Department of Anesthesiology, Amsterdam UMC, Cardiovascular Sciences, University of Amsterdam, Amsterdam, The Netherlands
1 shared publication - Elena Rampanelli
Department of Experimental Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 24 September 2019
- Published by F1000 Research Ltd in F1000Research
- Vol. 7, 1197
NLRX1 is not involved in the host defense against Escherichia coli induced pyelonephritis
Background: Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (E. coli) are one of the most prominent infections that have serious impact on kidney functioning and the development of chronic kidney disease. NOD-like receptor (NLR)X1 is an innate immune receptor that is important for immune metabolism and regulation, with as yet an unknown role in UTI and the pathophysiology of pyelonephritis. Methods: Wild-type (WT) and NLRX1 Knock-out (KO) female mice were subjected to UTI by intravesically inoculation of uropathogenic E. coli and sacrificed at 24h and 48h after infection after which bacterial burden and the inflammatory response in the bladder and kidney were studied. Ex vivo we studied the role of NLRX1 during the LPS induced pro-inflammatory cytokine response and phagocytosis of E. coli by granulocytes and monocytes. Results: Here, we report that during early experimental UTI NLRX1 absence reduces bacterial clearance in the bladder and dampens the inflammatory cytokine response, whereas in the kidney NLRX1 does not affect bacterial burden or cytokine response. In addition, we found that NLRX1 is not essential for the pro-inflammatory cytokine secretion by granulocytes and monocytes in response to LPS nor for bacterial phagocytosis. Conclusion: Together, we report that NLRX1 is important in enhancing the early host defense against uropathogenic E. coli in the bladder but does not affect the development of pyelonephritis.
- 24 September 2019
- Published by F1000 Research Ltd in F1000Research
- Vol. 7, 1197
Open AccessNLRX1 is not involved in the host defense against Escherichia coli induced pyelonephritis
Background: Urinary tract infections (UTIs) caused by uropathogenic Escherichia coli (E. coli) are one of the most prominent infections that have serious impact on kidney functioning and the development of chronic kidney disease. NOD-like receptor (NLR)X1 is an innate immune receptor that is important for immune metabolism and regulation, with as yet an unknown role in UTI and the pathophysiology of pyelonephritis. Methods: Wild-type (WT) and NLRX1 Knock-out (KO) female mice were subjected to UTI by intravesically inoculation of uropathogenic E. coli and sacrificed at 24h and 48h after infection after which bacterial burden and the inflammatory response in the bladder and kidney were studied. Ex vivo we studied the role of NLRX1 during the LPS induced pro-inflammatory cytokine response and phagocytosis of E. coli by granulocytes and monocytes. Results: Here, we report that during early experimental UTI NLRX1 absence reduces bacterial clearance in the bladder and dampens the inflammatory cytokine response, whereas in the kidney NLRX1 does not affect bacterial burden or cytokine response. In addition, we found that NLRX1 is not essential for the pro-inflammatory cytokine secretion by granulocytes and monocytes in response to LPS nor for bacterial phagocytosis. Conclusion: Together, we report that NLRX1 is important in enhancing the early host defense against uropathogenic E. coli in the bladder but does not affect the development of pyelonephritis.
- Open Access
- 16 June 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (8) , 2405-2420
NLRX1 dampens oxidative stress and apoptosis in tissue injury via control of mitochondrial activity
Mitochondrial dysfunction is the most prominent source of oxidative stress in acute and chronic kidney disease. NLRX1 is a receptor of the innate immune system that is ubiquitously expressed and localized in mitochondria. We investigated whether NLRX1 may act at the interface of metabolism and innate immunity in a model of oxidative stress. Using a chimeric mouse model for renal ischemia-reperfusion injury, we found that NLRX1 protects against mortality, mitochondrial damage, and epithelial cell apoptosis in an oxidative stress–dependent fashion. We found that NLRX1 regulates oxidative phosphorylation and cell integrity, whereas loss of NLRX1 results in increased oxygen consumption, oxidative stress, and subsequently apoptosis in epithelial cells during ischemia-reperfusion injury. In line, we found that NLRX1 expression in human kidneys decreased during acute renal ischemic injury and acute cellular rejection. Although first implicated in immune regulation, we propose that NLRX1 function extends to the control of mitochondrial activity and prevention of oxidative stress and apoptosis in tissue injury.
- 16 June 2017
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 214 (8) , 2405-2420
Open AccessNLRX1 dampens oxidative stress and apoptosis in tissue injury via control of mitochondrial activity
Mitochondrial dysfunction is the most prominent source of oxidative stress in acute and chronic kidney disease. NLRX1 is a receptor of the innate immune system that is ubiquitously expressed and localized in mitochondria. We investigated whether NLRX1 may act at the interface of metabolism and innate immunity in a model of oxidative stress. Using a chimeric mouse model for renal ischemia-reperfusion injury, we found that NLRX1 protects against mortality, mitochondrial damage, and epithelial cell apoptosis in an oxidative stress–dependent fashion. We found that NLRX1 regulates oxidative phosphorylation and cell integrity, whereas loss of NLRX1 results in increased oxygen consumption, oxidative stress, and subsequently apoptosis in epithelial cells during ischemia-reperfusion injury. In line, we found that NLRX1 expression in human kidneys decreased during acute renal ischemic injury and acute cellular rejection. Although first implicated in immune regulation, we propose that NLRX1 function extends to the control of mitochondrial activity and prevention of oxidative stress and apoptosis in tissue injury.